Clinical TrialsSearch results
Number of results: 623
- Recruitment status
- Title of the study
- Health Condition
- Primary sponsor
- Date of registration
Recruiting
- Testing the addition of the immunotherapy drug pembrolizumab to the usual chemotherapy treatment (paclitaxel and carboplatin) in endometrial cancer
- Endometrial Cancer
- Fujiwara Keiichi
- 2021-12-25
Recruiting
- Late phase II study of NS-304 in patients with intermittent claudication (IC) resulting from arteriosclerosis obliterans (ASO)
- Arteriosclerosis obliterans (ASO)
- Taira Masafumi
- 2021-12-17
Recruiting
- Phase 3 Study of Ravulizumab in Thrombotic Microangiopathy Associated With a Trigger
- thrombotic microangiopathy (TMA) associated with a trigger
- Yokosawa Jun
- 2021-12-17
Recruiting
- MK-4280A Versus Standard of Care in Previously Treated Metastatic PD-L1 positive Colorectal Cancer
- Previously treated metastatic PD-L1 positive colorectal cancer
- Nohata Nijiro
- 2021-12-13
Not yet recruiting
- Changes in medial elbow joint during selective exercise of forearm flexor-pronator muscles
- prevention of UCL injuries
- Yutaka Sawada
- 2021-12-12
Recruiting
- A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease
- Alzheimer Disease
- Yoshimoto Yusuke
- 2021-11-24
Recruiting
- An Open-label, Randomized Phase 3 Study of Immune and Targeted Combination Therapies, as First-line Treatment in Participants with Advanced ccRCC
- Renal cell carcinoma
- Tomohiro Yamaguchi
- 2021-11-19
Other
- A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease
- Atherosclerotic Cardiovascular Disease
- Hirata Takashi
- 2021-10-29
Not yet recruiting
- Phase II study of pembrolizumab and bevacizumab in combination with platinum-based chemotherapy followed by pembrolizumab, bevacizumab and olaparib in patients with platinum-sensitive recurrent ovarian cancer
- ovarian cancer
- Hasegawa Kosei
- 2021-10-29
Recruiting
- A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
- Early Breast Cancer
- Tanja Badovinac Crnjevic
- 2021-10-02